Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues, have been found to affect gut motility
While more large-scale, double-blind clinical trials specific to Long COVID and ME/CFS cohorts are urgently needed, the existing combination of rigorous pharmacokinetic data and compelling patient outcomes solidifies L-Glutathione as a premier therapeutic tool in chronic illness management
Both agonists affect cancer in vitro by decreasing the proliferation and metabolic pathways at varying concentrations
Compounding involves modifying FDA-approved drugs to meet individual patient needs, such as adjusting dosages, changing administration methods, or removing allergens the kind of customization Rising is now relying on to access tirzepatide
This month, Katz Institute for Womens Health sat down with Berta Kadosh, DO , Internal Medicine & Weight Management Specialist